Biogen’s $900 million settlement signals scrutiny on speaker fees
Pharmaceutical Technology
OCTOBER 5, 2022
In 2020, the US Department of Health and Human Services (HHS) Office of Inspector General released a special fraud alert showing its skepticism surrounding speaker programs like those conducted by Biogen for its MS drugs. At the same time, companies need to prioritize their compliance programs. Biogen’s activity in multiple sclerosis.
Let's personalize your content